Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ5WN8)

• Drug Name: Cyclopropylamine derivative 10 Drug Info
• Synonyms: PMID27019002-Compound-33b
• Cross-matching ID: TTD Drug ID: DMZ5WN8

Molecule-Related Drug Atlas

Drug(s) Targeting Lysine-specific histone demethylase 1 (LSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IMG-7289	DML9AVG	Acute myeloid leukaemia	2A60	Phase 2	[2]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[2]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[3]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[4]
ORY-2001	DMYM0UY	Alzheimer disease	8A20	Phase 2	[5]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[6]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[7]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[8]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Monoamine oxidase (MAO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[9]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[9]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[9]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[9]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[10]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[9]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[9]
Ergoloid mesylate	DMORPBA	Alzheimer disease	8A20	Approved	[11]
Cyclopropylamine derivative 11	DMMJ0YN	N. A.	N. A.	Patented	[1]
PMID27019002-Compound-20a	DMRX748	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysine-specific histone demethylase 1 (LSD)	TTNR0UQ	KDM1A_HUMAN	Inhibitor	[1]
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[1]

References

• [1] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
• [4] Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
• [5] Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
• [6] A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
• [7] Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
• [8] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [9] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [10] Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.